In the study of congenital hyperinsulinism now enrolling phase III sunRIZE trial

sunrize logo

Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy

Back to Careers